2020-08-302020-08-302017Stasevych, M., Zvarych, V., Lunin, V., Deniz, N. G., Gokmen, Z., Akgun, O., ... & Novikov, V. (2017). Computer-aided prediction and cytotoxicity evaluation of dithiocarbamates of 9, 10-anthracenedione as new anticancer agents. SAR and QSAR in Environmental Research, 28(5), 355-366.1062-936X1029-046Xhttps://doi.org/10.1080/1062936X.2017.1323796https://hdl.handle.net/20.500.12713/922Anticancer activity as an associated action for a series of dithiocarbamates of 9,10-anthracenedione was predicted using the PASS computer program and analysed with PharmaExpert software. The predicted cytotoxic activity of the dithiocarbamate derivatives of 9,10-anthracenedione was evaluated in vitro on cancer cells of the human lung (A549), prostate (PC3), colon (HT29) and human breast (MCF7) using the sulforhodamine B (SRB) cell viability assay. Among these compounds, 9,10-dioxo-9,10-dihydroanthracen-1-yl pyrrolidin-1-carbodithioate and 9,10-dioxo-9,10-dihydroanthracen-2-yl pyrrolidin-1-carbodithioate were identified as the most potent anticancer agents with cytotoxic activity against the MCF-7 human breast cell line with GI(50) values of 1.40 M and 1.52 M, whereas the GI(50) value for the reference anticancer drug mitoxantrone was 3.93 M. Thus, anticancer activity predicted by PASS with a probability Pa > 30% was confirmed by the experiment. Relatively small Pa values estimated by PASS indicated the novelty of the considered derivatives comparing to the compounds from the PASS training set.eninfo:eu-repo/semantics/closedAccessDithiocarbamates Of 910-AnthracenedioneAnticancer ActivityComputer-Aided PredictionPassCell Line Cytotoxicity PredictorPharmaexpertArticle28535536628524703WOS:0004029941000012-s2.0-85019597292Q110.1080/1062936X.2017.1323796Q3